Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Capecitabine + DCSZ11 + Oxaliplatin |
| Synonyms | CAPOX + DCSZ11 |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Capecitabine | Xeloda | R340|Ro 09-1978/000 | Chemotherapy - Antimetabolite 14 | Xeloda (capecitabine) is a prodrug that is converted to 5-FU, ultimately inhibiting RNA and DNA synthesis and cell division (PMID: 28520372). Xeloda (capecitabine) is FDA-approved for use in patients with colorectal, breast, gastric, esophageal, gastroesophageal junction, and pancreatic cancer (FDA.gov). |
| DCSZ11 | DCSZ-11|DCSZ 11 | DCSZ11 is a monoclonal antibody that targets an epitope of C1QR1 (CD93) and prevents the interaction of C1Q1R and its ligand IGFBP7, potentially resulting in decreased tumor cell proliferation and increased immune cell infiltration in the tumor microenvironment (NCI Drug DIctionary). | ||
| Oxaliplatin | Eloxatin | Diaminocyclohexane Oxalatoplatinum | Chemotherapy - Platinum 7 | Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07580339 | Phase II | Capecitabine + DCSZ11 + Oxaliplatin | Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer | Not yet recruiting | USA | 0 |